Best Places to Work

Found 11,132 articles

• Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor & a BCL-2 Inhibitor

  12/1/2023

  Eli Lilly and Company announced that the U.S. Food and Drug Administration approved Jaypirca® for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a Bruton's tyrosine kinase inhibitor and a BCL-2 inhibitor.

• GenScript Named a BioSpace 2024 Best Place to Work

  12/1/2023

  GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has been named among the Top 30 Large Employers as a BioSpace 2024 Best Place to Work.

• Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

  12/1/2023

  Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.

• Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink

  12/1/2023

  Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink.

• Thermo Fisher Scientific and Project HOPE Partner to Advance Health Equity Among HIV Positive Youth in Sub-Saharan Africa

  12/1/2023

  Thermo Fisher Scientific Inc. and Project HOPE today announced a new partnership to improve the wellbeing and treatment outcomes of adolescents and young persons living with HIV in Nigeria.

• FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

  11/30/2023

  Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has accepted for priority review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev, an antibody-drug conjugate, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.

• Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors

  11/30/2023

  Johnson & Johnson announced that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors.

• Acclinate Collaborates with Merck to Increase Clinical Trial Diversity

  11/30/2023

  Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck's oncology clinical studies.

• AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

  11/30/2023

  AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).

• Bayer and CrossBay Medical to develop novel Intrauterine System Inserter

  11/30/2023

  Bayer and CrossBay Medical Inc., today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer’s leading hormonal IUS portfolio.

• Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023

  11/30/2023

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the “Largest Employer” category.

• Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

  11/30/2023

  Femasys Inc. today announced the appointment of James Liu, M.D., as Chief Medical Officer.

• Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

  11/30/2023

  Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY).

• Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

  11/30/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy ® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.

• Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology

  11/30/2023

  Presage Biosciences has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company.

• Johnson & Johnson MedTech Acquires Laminar, Inc.

  11/30/2023

  Johnson & Johnson MedTech 1 today announced the completion of the acquisition 2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).

• Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

  11/29/2023

  Astellas Pharma Inc. will present 24-week results from the Phase 3b DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant in an oral presentation on November 30 at the 15th Congress of the European Society of Gynecology in Amsterdam, The Netherlands.

• AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)

  11/29/2023

  AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).

• Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences

  11/28/2023

  Thermo Fisher Scientific Inc., the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis.

• Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older

  11/28/2023

  Merck, known as MSD outside of the United States and Canada, announced results from STRIDE-3, a Phase 3 trial evaluating V116, the company’s investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults.